Response to Salvage Treatment in Recurrent Ovarian Cancer Treated Initially with Paclitaxel and Platinum-Based Combination Regimens

Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer

“…25 However, most patients relapse and, in this case, the time to progression tends to be brief, and the side effects of the salvage therapy are significant. 26 The response rate in platinum-based second-line therapy after a failed first-line treatment with platinum-containing cytostatics is dependent on the duration of the therapy-free interval, and ranges from 13% to 33%. 1,[27][28][29] Median survival time after salvage chemotherapy of recurrent ovarian cancer observed in clinical studies was 7-12 months.…”

Paclitaxel Derivatives for Targeted Therapy of Cancer: Toward the Development of Smart Taxanes

“…The resulting conjugate, designated , was soluble to the upper limit of tested concentrations (250 mg/mL). The conjugate completely retained the receptor binding properties of the attached peptide as compared with those of the unconjugated BBN [7][8][9][10][11][12][13]. In experiments with NCI-H1299 human nonsmall cell lung cancer cells, the cytotoxicity of the PTXPEGBBN[7-13] conjugate at a 15 nM dose was enhanced by a factor of 17.3 for 24 h and 10 for 96 h exposure times, relative to paclitaxel.…”

“…Accordingly, we synthesized a ternary conjugate consisting of paclitaxel (PTX), poly(ethylene glycol) (PEG), and a bombesin (BBN)/gastrin-releasing peptide (GRP) receptor-recognizing peptide (BBN [7][8][9][10][11][12][13]) 20 as the first member of a series of soluble tumor-targeting paclitaxel derivatives (Scheme 1). These novel molecules were designed based on the premise that the soluble conjugate will be guided by the receptor-specific peptide to bind to tumor cell surface receptors, and that after internalization, the paclitaxel-PEG bond will be hydrolytically and/or enzymatically cleaved to release the cytotoxic agent.…”

“…10,11 Reported side effects of the drug include neutropenia, mucositis, and cardiac and neurological toxicities in addition to hypersensitivity. [12][13][14][15][16] It would be highly desirable, therefore, to develop a mechanism through which a soluble paclitaxel derivative could be delivered specifically to the site of the disease in a targeted fashion. Possible advantages of such an approach may include (i) elimination of allergenic surfactants from the formulation due to increased solubility, (ii) efficient delivery of the drug to micrometastatic tumors, and (iii) reduction of the administered dose as a result of site-specific delivery of the drug.…”

Duration of second or greater complete clinical remission in ovarian cancer: Exploring potential endpoints for clinical trials

“…This illustrates the importance of TFI, but this study did not distinguish the proportion of patients with completely responding disease. [25] Clearly the length of the TFI has a major impact on the likelihood of subsequent response (including complete responses), and has been shown to affect PFS following second-line therapy. [26] However, the impact on the duration of second complete response was unknown.…”